Skip to main content
Article thumbnail
Location of Repository

Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation

By Sylvia Borchers, Melanie Bremm, Thomas Lehrnbecher, Elke Dammann, Brigitte Pabst, Benno Wölk, Ruth Esser, Meral Yildiz, Matthias Eder, Michael Stadler, Peter Bader, Hans Martin, Andrea Jarisch, Gisbert Schneider, Thomas Klingebiel, Arnold Ganser, Eva Maria Mischak-Weissinger and Ulrike Köhl


Background: Reconstitution of cytomegalovirus-specific CD3+CD8+ T cells (CMV-CTLs) after allogeneic hematopoietic stem cell transplantation (HSCT) is necessary to bring cytomegalovirus (CMV) reactivation under control. However, the parameters determining protective CMV-CTL reconstitution remain unclear to date.\ud \ud Design and Methods: In a prospective tri-center study, CMV-CTL reconstitution was analyzed in the peripheral blood from 278 patients during the year following HSCT using 7 commercially available tetrameric HLA-CMV epitope complexes. All patients included could be monitored with at least CMV-specific tetramer.\ud \ud Results: CMV-CTL reconstitution was detected in 198 patients (71%) after allogeneic HSCT. Most importantly, reconstitution with 1 CMV-CTL per µl blood between day +50 and day +75 post-HSCT discriminated between patients with and without CMV reactivation in the R+/D+ patient group, independent of the CMV-epitope recognized. In addition, CMV-CTLs expanded more daramtaically in patients experiencing only one CMV-reactivation than those without or those with multiple CMV reactivations. Monitoring using at least 2 tetramers was possible in 63% (n = 176) of the patients. The combinations of particular HLA molecules influenced the numbers of CMV-CTLs detected. The highest CMV-CTL count obtained for an individual tetramer also changed over time in 11% of these patients (n = 19) resulting in higher levels of HLA-B*0801 (IE-1) recognizing CMV-CTLs in 14 patients.\ud \ud Conclusions: Our results indicate that 1 CMV-CTL per µl blood between day +50 to +75 marks the beginning of an immune response against CMV in the R+/D+ group. Detection of CMV-CTL expansion thereafter indicates successful resolution of the CMV reactivation. Thus, sequential monitoring of CMV-CTL reconstitution can be used to predict patients at risk for recurrent CMV reactivation

Topics: ddc:610
Year: 2012
OAI identifier:

Suggested articles


  1. (2008). Analytical performance of a standardized single-platform MHC tetramer assay for the identification and enumeration of CMV-specific CD8+ T lymphocytes.
  2. (2007). Bioinformatic integration of biomechanics makes HLA sequencing universally applicable.
  3. (2006). CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation.
  4. (2010). Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.
  5. (2004). Clinical aspects of CMV infection after stem cell transplantation.
  6. (2005). Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection. Biology of blood and marrow transplantation :
  7. (2003). Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biology of blood and marrow transplantation :
  8. (2010). Cytomegalovirus infection/disease after hematopoietic stem cell transplantation.
  9. (2010). Cytomegalovirus-specific CD8+T cells targeting different HLA/peptide combinations correlate with protection but at different threshold frequencies.
  10. (2002). Definitions of cytomegalovirus infection and disease in transplant recipients.
  11. (2001). Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation.
  12. (2004). Enumeration of antigen-specific CD8+ T lymphocytes by single-platform, HLA tetramer-based flow cytometry: a European multicenter evaluation.
  13. (2005). Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A*02 or HLA-A*24 phenotype undergoing hematopoietic stem cell transplantation.
  14. (2010). Evidence for a bidirectional relationship between cytomegalovirus replication and acute graftversus-host disease. Biol Blood Marrow Transplant [Epub ahead of print].
  15. (2008). Expansion of Human Cytomegalovirus (HCMV) Immediate-Early 1-Specific CD8(+)T Cells and Control of HCMV Replication after Allogeneic Stem Cell Transplantation.
  16. (2008). Fatal cytomegalovirus pneumonia in patients with haematological malignancies: an autopsy-based case-control study.
  17. (2007). Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis.
  18. (2002). HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy.
  19. (2009). Human cytomegalovirus-specific CD4+ and CD8+ T cell responses in primary infection of the immunocompetent and the immunocompromised host.
  20. (2009). Human cytomegalovirus-specific T cell reconstitution in young patients receiving T celldepleted, allogeneic hematopoietic stem cell transplantation.
  21. (2002). Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus.
  22. (2002). Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells.
  23. (2001). Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes.
  24. (2010). Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study.
  25. (2008). ISHAGE-based single-platform flowcytometric analysis for measurement of absolute viable T cells in fresh or cryopreserved products: CD34/CD133 selected or CD3/CD19 depleted stem cells, DLI and purified CD56+CD32 NK cells.
  26. (2010). Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection.
  27. (2010). Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
  28. (2008). Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study.
  29. (2010). Multiple viral infections post-hematopoietic stem cell transplantation are linked to the appearance of chronic GVHD among pediatric recipients of allogeneic grafts.
  30. (2010). Multivariate analyses of immune reconstitution in children after alloSCT: risk-estimation based on age-matched leukocyte sub-populations.
  31. (1997). Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture.
  32. (2005). Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells.
  33. (2008). Reconstitution of cytomegalovirus specific T cells after pediatric allogeneic stem cell transplantation: results from a pilot study using a multi-allele CMV tetramer group.
  34. (2004). Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation.
  35. (2003). Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles.
  36. (2007). T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection.
  37. (2011). Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
  38. (2001). Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.